TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05056740

Intervention type: BIOLOGICAL
Intervention: Data analysis
Description: Analysis of the data from routine care at the end of the diagnostic work-up

Intervention type: BIOLOGICAL
Intervention: Data analysis
Description: Analysis of the data from routine care at the end of the diagnostic work-up

Intervention type: BIOLOGICAL
Intervention: Data analysis
Description: Analysis of the data from routine care at the end of the diagnostic work-up

Intervention type: BIOLOGICAL
Intervention: Data analysis
Description: Analysis of the data from routine care at the end of the diagnostic work-up
Study: NCT05782309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flavanol
Description: Assessement, supplementation for 30 days with either Placebo or Flavanols, Re-assessment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Assessement, supplementation placebo for 30 days with either Placebo or Flavanols, Re-assessment
Study: NCT00147472

Intervention type: OTHER
Group type: OTHER
Intervention: PET scan in addition to conventional CT imaging
Description: PET scans, Pre and post radiation treatment
Study: NCT03960268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brodalumab
Description: interleukin 17 receptor A antagonist
Study: NCT00774995

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EngerixTM-B
Description: Intramuscular injection, one dose.
Study: NCT00218023

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Contingency management (CM)
Description: Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during phase I) and medication compliance (during phase II).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Description: Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II. This therapy component focused on coping-skills training for resisting cocaine use in high-risk situations, based on relapse-prevention theory and manual-guided techniques. Therapy sessions were conducted by master's-level licensed professional counselors supervised by a licensed clinical psychologist, who monitored manual adherence and competency.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Description: Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II. This therapy component focused on coping-skills training for resisting cocaine use in high-risk situations, based on relapse-prevention theory and manual-guided techniques. Therapy sessions were conducted by master's-level licensed professional counselors supervised by a licensed clinical psychologist, who monitored manual adherence and competency.
Study: NCT02472431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intracavernosal administration of autologous ADRC
Description: Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After isolation autologous ADRC suspension will be injected intracavernosally.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADRC isolation
Description: ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
Study: NCT03531684

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MMFS-205-SR
Description: Twice daily, oral, 500 mg tablets

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily, oral
Study: NCT05071235

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LG1 (LLLT group 1)
Description: Application of LLLT (low-level laser therapy) AsGa 904 nm 10 J/cm².

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LG2 (LLLT group 2)
Description: Application of LLLT (low-level laser therapy) AsGa 904 nm 8 J/cm².

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LG3 (LLLT group 3)
Description: Application of LLLT (low-level laser therapy) AsGa 904 nm 4 J/cm².

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CG (control group)
Description: Application of placebo LLLT (low-level laser therapy), that is, with the device turned off.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Dressing
Description: Application of Helianthus annuus oil dressing.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dressing
Description: Application of Helianthus annuus oil dressing.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dressing
Description: Application of Helianthus annuus oil dressing.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dressing
Description: Application of Helianthus annuus oil dressing.
Study: NCT00359073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast
Description: 10 mg everyday

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: like placebo
Study: NCT02164084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB204
Description: SB204 Gel with hydrogel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Vehicle Gel with hydrogel
Study: NCT00774995

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EngerixTM-B
Description: Intramuscular injection, one dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EngerixTM-B
Description: Intramuscular injection, one dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EngerixTM-B
Description: Intramuscular injection, one dose.
Study: NCT03168347

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Anecdotal Evidence
Description: Communicate basic information on the therapeutic effect of a drug using only anecdotal evidence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Research Study Evidence
Description: Communicate basic information on the therapeutic effect of a drug using only research study evidence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Anecdotal + Research Study Evidence
Description: Communicate basic information on the therapeutic effect of a drug using only anecdotal and research study evidence.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No Evidence
Description: Communicate basic information on the therapeutic effect of a drug using neither anecdotal evidence nor research study evidence.
Study: NCT00218023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Description: Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II. This therapy component focused on coping-skills training for resisting cocaine use in high-risk situations, based on relapse-prevention theory and manual-guided techniques. Therapy sessions were conducted by master's-level licensed professional counselors supervised by a licensed clinical psychologist, who monitored manual adherence and competency.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Description: Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II. This therapy component focused on coping-skills training for resisting cocaine use in high-risk situations, based on relapse-prevention theory and manual-guided techniques. Therapy sessions were conducted by master's-level licensed professional counselors supervised by a licensed clinical psychologist, who monitored manual adherence and competency.
Study: NCT02763007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alogliptin+pioglitazone
Description: alogliptin and pioglitazone add on metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alogliptin
Description: nesina add on metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: actos add on metformin
Study: NCT00656422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin Levemir
Description: The participant will receive an insulin dose of insulin Levemir at dinner subcutaneously according to a dosing algorithm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin Lantus
Description: The participant will receive an insulin dose of the insulin Lantus at dinner subcutaneously according to a dosing algorithm.
Study: NCT01015534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole brain irradiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole brain irradiation
Study: NCT01698463

Intervention type: OTHER
Group type: OTHER
Intervention: Identification of patients at risk, tailored exercise prescription, motivational interviewing, review of behavioural outcomes
Description: The intervention was delivered in two visits and two follow-up phone calls.~* Physician identifies that the patient is at risk of falls or fractures~* Visit one: individualized exercise prescription by a physiotherapist.~* Visit two: motivational interviewing (behavioural counselling) by kinesiologist~* Phone call 1 and 2: Kinesiologist reviews behavioural components (action planning, coping planning, coping self-efficacy, intentions.
Study: NCT03604224

Intervention type: DRUG
Intervention: Canagliflozin 300 mg
Description: Participants who are initiated on canagliflozin 300 mg will be observed. No study treatment will be administered as a part of this study.
Study: NCT02998645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: Film-coated tablets (12.5 mg, 25 mg, 50 mg and 75 mg) administered orally, once daily for up to 6 months. East and Southeast Asian participants were treated with 100 mg once daily, to adjust for the lower apparent clearance of eltrombopag. All other participants were treated with 150 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Supplied as oral soft gel capsules. The starting dose was based on body weight at 10.0 mg/kg/day (acceptable rounding range was from 9.5 to 10.5 mg/kg/day) in divided doses every 12 hours. After Day 1, dosing was titrated individually according to therapeutic trough level between 200 and 400 μg/L for 6 months. After 6 months (only for responders at Month 6), tapering of cyclosporine was done as follows:~* 6-9 months: at the 6 months visit, the dose was reduced by 25% for 3 months~* 9-12 months: at the 9 months visit, the dose was further reduced by 25% for another 3 months~* 12-24 months: dose was maintained
Study: NCT00839488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pantoprazole 40 mg iv
Description: pnatoprazole 40 mg iv qd
Study: NCT04865757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Space Flap
Description: A space flap is formed out of Palacos®, adjusted to the skull surface with temporal augmentation
Study: NCT04661345

Intervention type: OTHER
Intervention: Proteomic analysis of synovial fluids
Description: Characterization of the proteome of infected/aseptic synovial fluid for the identification of molecular hallmarks strictly related to the presence of a bacterial infection mediated by coagulase-negative Staphylococci

Intervention type: OTHER
Intervention: Proteomic analysis of synovial fluids
Description: Characterization of the proteome of infected/aseptic synovial fluid for the identification of molecular hallmarks strictly related to the presence of a bacterial infection mediated by coagulase-negative Staphylococci
Study: NCT04366648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JK-1201I
Description: malignant solid tumor that has been confirmed by histopathology and/or cytology

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JK-1201I
Description: malignant solid tumor that has been confirmed by histopathology and/or cytology

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JK-1201I
Description: malignant solid tumor that has been confirmed by histopathology and/or cytology

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JK-1201I
Description: malignant solid tumor that has been confirmed by histopathology and/or cytology

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JK-1201I
Description: malignant solid tumor that has been confirmed by histopathology and/or cytology
Study: NCT02823782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI and neuropsychological assessment planned for the study for patient and volunteers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI and neuropsychological assessment planned for the study for patient and volunteers

Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: MRI and neuropsychological assessment planned for the study for patient and volunteers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI and neuropsychological assessment planned for the study for patient and volunteers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuropsychological assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuropsychological assessment

Intervention type: OTHER
Group type: OTHER
Intervention: neuropsychological assessment
Study: NCT04661345

Intervention type: OTHER
Intervention: Proteomic analysis of the isolated coagulase-negative Staphylococci
Description: Characterization of the secretome of coagulase-negative Staphylococci isolated from infected prosthetic implants
Study: NCT02823782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neuropsychological assessment
Study: NCT03548584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Oral tablets

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablets
Study: NCT02533921

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interdisciplinary outpatient palliative care
Description: Interdisciplinary outpatient palliative care is an approach to caring for individuals with life-threatening illnesses that addresses potential causes of suffering including physical symptoms such as pain, psychiatric symptoms such as depression, psychosocial issues and spiritual needs. Palliative care approaches have been successfully applied to improve patient-centered outcomes in cancer as well as several chronic progressive illnesses including heart failure and pulmonary disease.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Usual care defined as including both a PCP and neurologist
Study: NCT03865290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8mg
Description: Oral Ondansetron 8 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8mg
Description: Oral Ondansetron 8 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8mg
Description: Oral Ondansetron 8 mg
Study: NCT01728376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: Intravenous daptomycin given at 7 mg/kg (ages 12-17 years); 9 mg/kg (ages 7-11 years); 12 mg/kg (ages 1-6 years) infused once daily, intravenously, over 30 or 60 minutes. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: Intravenous daptomycin given at 7 mg/kg (ages 12-17 years); 9 mg/kg (ages 7-11 years); 12 mg/kg (ages 1-6 years) infused once daily, intravenously, over 30 or 60 minutes. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Description: Intravenous daptomycin given at 7 mg/kg (ages 12-17 years); 9 mg/kg (ages 7-11 years); 12 mg/kg (ages 1-6 years) infused once daily, intravenously, over 30 or 60 minutes. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Vancomycin, Semi-synthetic penicillin, First-generation cephalosporins, Clindamycin: administered per standard of care. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.
Study: NCT03865290

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral matched placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral matched placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral matched placebo
Study: NCT02041598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHW Intervention
Description: 5 group educational sessions, 2 1v1 Visits with a CHW, Phone Calls as needed during 6-month study period
Study: NCT01532466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: All patients were given oxygen via a face mask. The patients were then administered with the following medications intravenously: the rocuronium group received rocuronium 0.06 mg kg-1, and the control group received the same volume of normal saline 30 s before the injection of an IV fentanyl bolus (1.5 mcg kg-1, within 2 s).
Study: NCT01728376

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Vancomycin, Semi-synthetic penicillin, First-generation cephalosporins, Clindamycin: administered per standard of care. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Vancomycin, Semi-synthetic penicillin, First-generation cephalosporins, Clindamycin: administered per standard of care. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.
Study: NCT01177735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Only enough CC-4047 for 1 cycle of therapy may be provided to the patient each cycle. Participants will receive CC-4047 4 mg/day for 21 days, every 28 days. Treatment will continue until disease recurrence or untoward toxicity.
Study: NCT03992326

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TIL
Description: Adoptive transfer of Autologous Tumor-Infiltrating Lymphocytes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered as an intravenous (IV) infusion for two days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered as an intravenous (IV) infusion for five days.
Study: NCT02944344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Four Conversations
Description: The online Four Conversations program consists of tutorial videos, printable documents, and live sessions with a counselor to educate subjects on shared decision making and care planning for those with advanced disease.
Study: NCT03992326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of eight doses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Low-dose irradiation (1Gy) will be administered using tomotherapy to up to 20 measurable tumor lesions once before TIL infusion.
Study: NCT04279834

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PAP Treatment
Description: Motivational enhancement plus remote-monitoring and participant self-monitoring of PAP use.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education I
Description: Motivational enhancement plus participant self-monitoring of sleep.
Study: NCT02594722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES-cycling
Description: Patients performed an endurance tests with functional electrical stimulation during 30 minutes with an oxygen uptake measure.
Study: NCT02944344

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Four Conversations
Description: The online Four Conversations program consists of tutorial videos, printable documents, and live sessions with a counselor to educate subjects on shared decision making and care planning for those with advanced disease.
Study: NCT02594722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Classic cycloergometer
Description: Patients performed an endurance tests on classic ergometer during 30 minutes with a sham electrical stimulation with an oxygen uptake measure.
Study: NCT04311034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48
Description: Participants will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, investigators believed that the subject could no longer benefit from treatment, or this study ended.
Study: NCT04216134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-labeled PSMA-11
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo 68GA-PSMA-11 PET
Study: NCT05492084

Intervention type: OTHER
Intervention: without Intervention
Description: without Intervention

Intervention type: OTHER
Intervention: without Intervention
Description: without Intervention
Study: NCT02753647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Study: NCT03731117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Furosemide (FUROSEMIDE®) 20 mg / 2ml, ampoule for injection~1 mg / kg slow intravenous injection 1.5 mg / kg if chronic exposure to diuretics in the week prior to inclusion Measurement of urine output after two and six hours. Compensation of diuresis by same volume of crystalloids over a 6-hour period
Study: NCT00589108

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sigma Knee System
Description: Sigma Knee System (mobile-bearing knee with the P.S. polyethylene insert)